Tamoxifen-mediated growth inhibition of human cholangiocarcinoma

Cancer Research

Volumn 57, Issue 9, 1997, Pages 1743-1749

  Sampson, Lorenzo K ^a   Vickers, Selwyn M ^a   Ying, Weizhong ^b   Phillips, John O ^b,c  

^a UAB Department of Surgery   (United States)

^b University of Alabama at Birmingham School of Medicine   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ESTRADIOL; ESTROGEN RECEPTOR; MESSENGER RNA; RECEPTOR PROTEIN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, NORTHERN; CELL DIVISION; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH INHIBITORS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PRECIPITIN TESTS; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0030941284     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Alpini, G., Phillips, J. O, and LaRusso, N. F. The biology of biliary epithelia. In: I. Arias, J. Boyer, N. Fausto, W. Jakoby, D. Schachter, and D. Shafritz (eds.), The Liver: Biology and Pathobiology, Ed. 3, pp. 623-653. New York: Raven Press, 1994.
2. Blumgart, L. H. Cancer of the bile ducts. In: Surgery of the Liver and Biliary Tract. In: L. M. Blumgart (ed.), pp. 829-853. Edinburgh: Churchill Livingstone, 1998.
3. Farley, D. R., Weaver, A. L., and Nargorney, D. M. Natural history of unresected cholangiocarcinoma. Patient outcome after noncurative intervention. Mayo Clin. Proc., 70: 425-429, 1995.
4. Lake, J. R. Benign and malignant neoplasms of the gallbladder, bile ducts, and ampulla. In: M. Sleisenger and J. Fordtran (eds.), Gastrointestinal Diseases: Pathophysiology/Diagnosis/Management, Ed. 5 pp. 1891-1902. Philadelphia: W. B. Saunders, 1993.
5. Van Leeuwen, D. J., Huibregtse, K., and Tytgat, G. N. J. Carcinoma of the hepatic confluence 25 years after Klatskin's description: diagnosis and endoscopic management. Semin. Liver Dis., 10: 102-113, 1990.
6. Gallagher, P. J., Millis, R. R., and Mitchinson, M. J. Congenital dilatation of the intrahepatic bile ducts With cholangiocarcinoma. J. Clin. Pathol. (Lond.), 25: 804-808, 1972.
7. Okuda, K., Kubo, Y., Okuzaki, K., Arishima, T., Hashimoto, M., Jinnouchi, S., Sawa, Y., Shimokawa, Y., Nakajima, Y., Noguchi, T., Nakano, M., Kojiro, M., and Nokashima, T. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: study of 57 autopsy-proven cases. Cancer (Phila.), 39: 232-246, 1977.
8. Purtile, D. T. Clonorchiasis and hepatic neoplasms. Trop. Geogr. Med., 28: 21-27, 1976.
9. Phillips, J. O., Weisner, R., and LaRusso, N. F. Sclerosing cholangitis. In: J. Kirsner (ed.), The Growth of Gastroenterologic Knowledge in the Twentieth Century, pp. 309-327. Malvern, PA: Lea and Febiger, 1994.
10. Santen, R. J., Manni, A., Harvey, H., and Redmond, C. Endocrine treatment of breast cancer in women. Endocr. Res., 11: 221-265, 1990.
11. Jordan, V. C. Long term adjuvant therapy for breast cancer. Breast Cancer Res. Treat., 15: 125-136, 1990.
12. Jiang, S. Y., and Jordan, V. C. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst., 84: 580-591, 1992.
13. Pollack, I. F., Randall, M. S., Kristofik, M. P., Kelly, R. H., Selker, R. G., and Vertosicky, F. T. Effects of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res., 50: 7134-7138, 1990.
14. Couldwell, W. T., Weiss, M. H., DiGiorgio, L. M., Weiner, L. P., Hinton, D. R., Ehsesmann, L. R., Corti, P. S., and Apuzzo, M. L. J. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery, 32: 485-490, 1993.
15. Thapar, K., Stetaneana, L., Kovacs, K., Scheithauer, B. W., Lloyed, R. V., Muller, P. J., and Laws, E. A. Estrogen receptor gene expression in craniopharyngiomas: an m situ hybridization study. Neurosurgery, 35: 1012-1017, 1994.
16. Knuth, A., Gabbert, H., Dippold, W., Klein, O., Sachsse, W., Bitter-Suermann, D., Prellwitz, W., and Zum Buschenfelde, K. H. M. Biliary adenocarcinoma: characterisation of three new human tumor cell lines. J. Hepatol., 1: 579-596, 1985.
17. Homma, S., Nagamori, S., and Fujisc, K. Human bile duct carcinoma cell line producing abundant mucin in vitro. Gastroenterol. Jpn., 22: 74-79, 1987.
18. Daffada, A. A. I., Johnston, S. R. D., Nicholls, J., and Dowsett, M. Detection of wild type and exon 5-deleted splice variant oestrogen receptor (ER) mRNA in ER-positive and -negative breast cancer cell lines by reverse transcription/polymerase chain reaction. J. Mol. Endocrinol., 13: 265-273, 1994.
19. Alpini, G., Ulrich, C., Phillips, J. O., Pham, L., Miller, L. J., and LaRusso, N. F. Upregulation of secretin receptor gene expression in rat cholangiocytes after bile duct ligation. Am. J. Physiol., 266: G922-G928, 1994.
20. Houghton, J. A., Moroda, S. J., Phillips, J. O., and Houghton, P. J. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res., 41: 144-149, 1982.
21. Ueno, Y., Phillips, J. O., Ludwig, J., and LaRusso, N. F. Development and characterization of an experimental model of immune-mediated cholangitis. Proc. Natl. Acad. Sci. USA, 93: 216-220, 1996.
22. Brunner, N., Bronzert, D., Vindelov, L. L., Rygarrd, K., Spang-Thomsen, M., and Lippman, M. E. Effect of growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res., 49: 1515-1520, 1989.
23. Castles, C. G., Fuqua, S. A. W., Klotz, D. M., and Hill, S. M. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res., 53: 5934-5939, 1993.
24. Greene, G. L., Sobel, N. B., King, W. J., and Jensen, E. V. Immunochemical studies of estrogen receptors. J. Steroid Biochem., 20: 51-56, 1984.
25. Greene, G., and Press, M. F. I. Steroid receptor structure (including monoclonal antibodies and new methods of determination). Structure and dynamics of the estrogen receptor. J. Steroid Biochem., 24: 1-7, 1986.
26. Jordan, V. C. An overview of consideration for the testing of tamoxifen as a preventative for breast cancer. Ann. NY Acad. Sci., 768: 141-147, 1995.
27. Henderson, I. C., Harris, J. R., Kinne, D. W., and Hellman, S. Cancer of the breast. In: V. T. De Vita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer, Principles and Practice of Oncology, pp. 1197-1268. Philadelphia: J. B. Lippincott, 1989.
28. Colletti, R. B., Roberts, J. D., Devlin, J. T., and Copeland, K. C. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res., 49: 1882-1884, 1989.
29. Noguchi, S., Motomura, K., Inaji, H., Imaoka, S., and Koyama, H. Down-regulation of transforming growth factor-α by tamoxifen in human breast cancer. Cancer (Phila.), 72: 131-136, 1993.
30. Roberts, A. B., and Sporn, M. B. The transforming growth factor-β. In: M. B. Sporn and A. B. Roberts (eds.), Handbook of Experimental Pharmacology, Vol. 95, pp. 419-472. Berlin: Springer-Verlag, 1990.
31. 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res., 52: 4261-4264, 1992.
32. Colletta, A. A., Wakefield, L. M., Howell, F. V., van Roozendaal, K. E. P., Danielpour, D., Ebbs, S. R., Sporn, M. B., and Baum, M. Anti-oestrogens induce the secretion of active transforming growth factor βfrom human fetal fibroblasts. Br. J. Cancer, 62: 405-409, 1990.
33. Perry, R. R., Kang, Y., and Greaves, B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg. Oncol., 2: 238-245, 1995.
34. Teixeira, C, Reed, J. C., and Pratt, M. A. C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res., 55: 3902-3907, 1995.
35. Sutherland, R. L., Murphy, L. C., Foo, M. S., Green, M. D., Whybourne, A. M., and Krozowski, Z. S. High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature (Lond.), 288: 273-275, 1980.
36. Greenberg, D. A., Carpenter, C. L., and Messing, R. O. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cell line. Cancer Res., 47: 70-74, 1987.
37. O'Brian, C. A., Liskamp, R. M., Solomon, D. H., and Weinstein, I. B. Inhibition of protein kinase C by tamoxifen. Cancer Res., 45: 2462-2465, 1985.
38. Ishii, M., Vroman, B. T., and LaRusso, N. F. Morphological demonstration of receptor mediated endocytosis of epidermal growth factor by isolated bile duct epithelial cells, Gastroenterology, 98: 1284-1291, 1990.
39. Tan, C. K., Podila, P. V., Taylor, J. E., Nagorney, D. M., Wiseman, G. A., Gores, G. J., and LaRusso, N. F. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology, 108: 1908-1916, 1995.
40. Vickers, S. M., Phillips, J. O., Kerby, J. D., Bynon, J. S., Thompson, J. A., and Curiel, D. T. In vivo gene transfer to the human biliary tract. Gene Ther., 3: 825-828, 1996.
41. 15Ink4B/MTS2 genes in biliary tract cancer. Cancer Res., 55: 2756-2760, 1995.
42. Eagon, P. K., Francavilla, A., DiLeo, A., Elm, M. S., Gennari, L., Mazzaferro, V., Colella, G. A., Van Thiel, D. H., and Starzl, T. E. Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. Dig. Dis. Sci., 36: 1303-1308, 1991.
43. Francavilla, A., Panella, C., Amoruso, A., Giangaspero, A., Gennari, L., Mazzaferro, V., Colella, G., Van Thiel, D. H., and Starzl, T. E. Role of estrogens and epidermal growth factor in hepatocellular carcinoma (HCC). Dig. Dis. Sci., 36: 1299-1302, 1991.
44. Villa, E., Camellini, L., Dugani, A., Zucchi, F., Grottola, A., Merighi, A., Buttafoco, P., Losi, L., and Manenti, F. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res., 55: 498-500, 1995.
45. S2 status in human breast cancer. Cancer Res., 55: 288-293, 1995.
46. Farinati, F., Salvagnini, M., DeMaria, N., Fornasiero, A., Chiaramonte, M., Rossaro, L., and Naccaroto, R. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J. Hepatol., 11: 297-301, 1990.
47. Martinez-Cerezo, F. J, M., Tomas, A., Donoso, L., Enroquez, J., Guarner, C., Balanzo, J., Martinez-Nogueras, A., and Vilardell, F. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J. Hepatol., 20: 702-706, 1994.
48. Jiang, S. Y., Shyu, R. Y., Yeh, M. Y., and Jordan, V. C. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J. Hepatology., 23: 712-719, 1995.